ArticleCost effectiveness and resource allocation : C/E2020

Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective.

Sarah Dewilde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.